baricitinib for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
COV-BARRIER (critically ill) NCT04421027		RCT	baricitinib	placebo	COVID-19 severe or critically	low	51/50	suggested	suggested 46 % decrease in deaths,death D28 with a high degree of certainty due to low risk of bias suggested 1.9-fold increase in clinical improvement with a high degree of certainty due to low risk of bias
1 study excluded by filtering options (0 RCT / 1 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis